Concord, MA, United States of America

Richard Chesworth

This inventor holds 107 USPTO granted patents and 58 published patent applications, plus 8 CIPO patents and 38 EPO patents, primarily in Protein Methyltransferase Inhibitors (CPC class C07D405-12). Top assignees: Epizyme, Inc., Envivo Pharmaceuticals, Inc., Forum Pharmaceuticals, Inc.. Active years: 2011-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard Chesworth. Retrieved from https://idiyas.com/inventor/richard-chesworth

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 107 

% Patents Active = 73.8

 

 

Average Co-Inventor Count = 4.4

ph-index = 27

Forward Citations = 1,747(Granted Patents)

Forward Citations (Not Self Cited) = 487(Dec 10, 2025)


Inventors with similar research interests:

🔬 See more inventors

Location History:

  • Boston, MA (US) (2011 - 2015)
  • Concord, MA (US) (2013 - 2023)

Company Filing History:


Years Active: 2011-2024

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
PRMT5 Inhibitors
CARM1 Inhibitors
Arginine Methyltransferase
Isoxazole Carboxamides
Substituted Piperidine
Pyrazole Derivatives
Heteroaryl Compounds
Bicyclic Compounds
Leukemia Treatment
SMYD Inhibitors
Dihydroisoquinoline
Protein Methyltransferase
107 patents (USPTO):Explore Patents

Title: Richard Chesworth: Pioneering Inventor Shaping the Future

Introduction:

Richard Chesworth, a visionary inventor based in Concord, MA, has dedicated his life to innovation and creating a positive impact on the world. With a total of 104 patents to his name, Chesworth's relentless pursuit of groundbreaking solutions has marked him as a true trailblazer in the field of technology.

Latest Patents:

Among his latest patents, "CARM1 inhibitors and uses thereof" stands out as a significant advancement in the medical field. These compounds are designed to inhibit CARM1 activity, offering promising avenues for treating CARM1-mediated disorders. Additionally, Chesworth's method for treating leukemia by administering DOT1L inhibitor compounds showcases his commitment to developing life-saving therapies.

Career Highlights:

Throughout his illustrious career, Chesworth has made significant contributions to companies such as Epizyme, Inc. and Envivo Pharmaceuticals, Inc. His expertise and innovative spirit have driven these organizations towards new frontiers in biotechnology and pharmaceuticals. Chesworth's strategic vision and inventive prowess have solidified his reputation as a pioneering inventor.

Collaborations:

Chesworth has collaborated with esteemed professionals in his field, including Gideon Shapiro and Kenneth William Duncan. Together, they have worked on groundbreaking projects, pushing the boundaries of technological innovation and medical research. These collaborations have not only enriched Chesworth's own work but have also inspired the next generation of inventors.

Conclusion:

In conclusion, Richard Chesworth's unwavering dedication to innovation and his passion for creating positive change have positioned him as a visionary inventor shaping the future of technology. His remarkable achievements in the realm of patents and inventions serve as a testament to his brilliance and his enduring legacy in the world of innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…